This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing United Therapeutics' TETON-2 Study Results of Nebulized Tyvaso® (Treprostinil) and Their Impact on the Treatment Landscape for Idiopathic Pulmonary Fibrosis (IPF)
Ticker(s): UTHR, RHHBY, LQDA, INSMWho's the expert?
Institution: Heart/Lung Transplant Center at Stanford and Pulmonary Fibrosis Foundation Care Center at Stanford
- Associate Medical Director for Lung and Heart/Lung Transplantation at Stanford and director of the Pulmonary Fibrosis Foundation Care Center at Stanford
- Manages over 100+ patients with idiopathic pulmonary fibrosis (IPF)
- Specializes in the care of interstitial lung disease and lung transplant patients
Interview GoalTo gain understanding of the TETON-2 Pivotal Study Results of Nebulized Tyvaso® (Treprostinil) and the prospective impact on the treatment landscape for idiopathic pulmonary fibrosis (IPF).
Are You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Sep 15, 2025
- Call Time
- 04:35 PM EDT
Wall Street Time
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
